loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Information, Expiry & Status of FDA Orange Book Patents covering 8685934

    Client Virtual Booth
    Menu

    AstraZeneca

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Send me more info on How To Grow My Business Digitally?

    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ASTRAZENECA AB (7)

    filter

    01 8685934 (7)

    filter

    01 Blank (7)

    filter

    01 Blank (7)

    filter

    01 2030-05-26 (7)

    refreshReset Filter
    refreshReset Filter
    price-trendAsk Us

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    205649
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    5
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    202293
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    2
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    202293
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    1
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    205649
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    3
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    205649
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    2
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    205649
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    1
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    ASTRAZENECA AB

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

    PDF Supplier PDF
    URL Supplier Web Content
    8685934
    2030-05-26
    U-1522
    205649
    TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN,
    4
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Post Enquiry
    POST ENQUIRY